Bristol-Myers Squibb (BASE:BMY) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BMY Overzicht aandelen

Bristol-Myers Squibb Company ontdekt, ontwikkelt, licenseert, produceert, verkoopt, distribueert en verkoopt wereldwijd biofarmaceutische producten.

Over het bedrijf

BMY fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	5/6

Beloningen

Verhandeld tegen 50.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 49.05% per jaar groeien

Risicoanalyse

Heeft een hoog schuldenniveau

Dividend van 4.54% wordt niet goed gedekt door de winst

Bristol-Myers Squibb Company Concurrenten

Zoetis

NYSE:ZTS

US$87.6b

Merck KGaA

XTRA:MRK

€71.6b

Sanofi

ENXTPA:SAN

€126.4b

GSK

LSE:GSK

UK£60.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bristol-Myers Squibb
Historische aandelenkoersen
Huidige aandelenkoers	US$21,150.00
52 Week Hoogtepunt	US$22,600.00
52 Week Laag	US$12,999.00
Bèta	0.46
11 maand verandering	4.83%
3 maanden verandering	12.65%
1 Jaar Verandering	12.29%
33 jaar verandering	450.21%
5 jaar verandering	2,303.43%
Verandering sinds IPO	80,217.26%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BMY	AR Pharmaceuticals	AR Markt
7D	3.0%	-1.1%	1.8%
1Y	12.3%	-6.6%	105.1%

Rendement versus industrie: BMY overtrof de AR Pharmaceuticals industrie, die het afgelopen jaar een rendement -10.9 % opleverde.

Rendement versus markt: BMY presteerde slechter dan AR Market, dat het afgelopen jaar een rendement van 177.6 % opleverde.

Prijsvolatiliteit

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	5.0%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	6.0%
10% most volatile stocks in AR Market	7.8%
10% least volatile stocks in AR Market	4.0%

Stabiele aandelenkoers: BMY heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van BMY is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company ontdekt, ontwikkelt, licenseert, produceert, verkoopt, distribueert en verkoopt wereldwijd biofarmaceutische producten. Het bedrijf biedt producten aan voor hematologie, oncologie, cardiovasculaire aandoeningen, immunologie, fibrotische aandoeningen en neurowetenschap. De producten van het bedrijf omvatten Eliquis voor vermindering van het risico op beroerte/systemische embolie bij niet-valvulair atriumfibrilleren en voor de behandeling van DVT/PE; Opdivo voor verschillende indicaties tegen kanker, waaronder blaas-, bloed-, CRC-, hoofd-hals-, RCC-, HCC-, long-, melanoom-, MPM-, maag- en slokdarmkanker; Pomalyst/Imnovid voor multipel myeloom; Orencia voor actieve reumatoïde artritis en artritis psoriatica; en Sprycel voor de behandeling van Philadelphia-chromosoom-positieve chronische myeloïde leukemie.

Bristol-Myers Squibb Company Samenvatting

Hoe verhouden de winst en inkomsten van Bristol-Myers Squibb zich tot de beurswaarde?
BMY fundamentele statistieken
Marktkapitalisatie	AR$105.83t
Inkomsten(TTM)	-AR$6.42t
Inkomsten(TTM)	AR$45.62t

2.3x

P/S-verhouding

-16.5x

Koers/Winstverhouding

Is BMY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BMY resultatenrekening (TTM)
Inkomsten	US$46.51b
Kosten van inkomsten	US$11.08b
Brutowinst	US$35.43b
Overige uitgaven	US$41.97b
Inkomsten	-US$6.54b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Oct 31, 2024

Winst per aandeel (EPS)	-3.23
Brutomarge	76.18%
Nettowinstmarge	-14.06%
Schuld/Eigen Vermogen Verhouding	306.9%

Hoe presteerde BMY op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.5%

Huidig dividendrendement

-74%

Uitbetalingsratio

Betaalt BMY een betrouwbaar dividend?

Zie BMY dividendgeschiedenis en benchmarks

Wanneer moet je BMY kopen om een aanstaand dividend te ontvangen?
Bristol-Myers Squibb dividenddata
Ex Dividend Datum	Apr 04 2024
Betaaldatum dividend	May 01 2025
Dagen tot Ex-dividend	200 days
Dagen tot dividendbetaaldatum	192 days

Betaalt BMY een betrouwbaar dividend?

Zie BMY dividendgeschiedenis en benchmarks

BMY Overzicht aandelen

Beloningen

Risicoanalyse

Bristol-Myers Squibb Company Concurrenten

NYSE:ZTS

US$87.6b

XTRA:MRK

€71.6b

ENXTPA:SAN

€126.4b

LSE:GSK

UK£60.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Recent updates

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Rendement voor aandeelhouders

Prijsvolatiliteit